Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer in the United States.
+ 2 more risks
Flawless balance sheet and overvalued.
Share Price & News
How has Phio Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 44R2's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 44R2 underperformed the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: 44R2 underperformed the German Market which returned 15% over the past year.
Price Volatility Vs. Market
How volatile is Phio Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Phio Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 44R2's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 44R2's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 44R2 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 44R2 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 44R2's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 44R2 is good value based on its PB Ratio (0.2x) compared to the DE Biotechs industry average (3.5x).
How is Phio Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 44R2 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 44R2 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 44R2 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 44R2 is forecast to have no revenue next year.
High Growth Revenue: 44R2 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 44R2's Return on Equity is forecast to be high in 3 years time
How has Phio Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 44R2 is currently unprofitable.
Growing Profit Margin: 44R2 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 44R2 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.7% per year.
Accelerating Growth: Unable to compare 44R2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 44R2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 44R2 has a negative Return on Equity (-104.87%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Phio Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: 44R2's short term assets ($9.3M) exceed its short term liabilities ($2.0M).
Long Term Liabilities: 44R2's short term assets ($9.3M) exceed its long term liabilities ($438.0K).
Debt to Equity History and Analysis
Debt Level: 44R2 is debt free.
Reducing Debt: 44R2 has not had any debt for past 5 years.
Inventory Level: 44R2 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 44R2's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 44R2 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 44R2 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -2.8% each year.
What is Phio Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 44R2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 44R2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 44R2's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 44R2's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 44R2's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Gerrit Dispersyn (44yo)
Dr. Gerrit Dispersyn, Dr. Med. Sc, serves as a Chief Executive Officer at Phio Pharmaceuticals Corp. (formerly knowns as at RXi Pharmaceuticals Corporation) since March 1, 2019. Dr. Dispersyn has been Pres ...
CEO Compensation Analysis
Compensation vs Market: Gerrit's total compensation ($USD535.88K) is about average for companies of similar size in the German market ($USD412.37K).
Compensation vs Earnings: Gerrit's compensation has increased whilst the company is unprofitable.
|Independent Chairman of the Board||8.1yrs||US$63.63k||0.65% $15.7k|
|Independent Director||6.8yrs||US$28.63k||0.022% $524.1|
|Independent Director||6.8yrs||US$33.63k||0.021% $513.0|
|Member of Scientific Advisory Board||5.6yrs||no data||no data|
|Member of Scientific Advisory Board||7.6yrs||no data||no data|
|Member of Scientific Advisory Board||2.8yrs||no data||no data|
|Member of Scientific Advisory Board||3yrs||no data||no data|
|Member of Scientific Advisory Board||7.6yrs||no data||no data|
|Independent Director||0.3yrs||US$18.33k||0.27% $6.5k|
Experienced Board: 44R2's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 553%.
Phio Pharmaceuticals Corp.'s company bio, employee growth, exchange listings and data sources
- Name: Phio Pharmaceuticals Corp.
- Ticker: 44R2
- Exchange: DB
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.617m
- Listing Market Cap: US$2.415m
- Shares outstanding: 866.49k
- Website: https://www.phiopharma.com
Number of Employees
- Phio Pharmaceuticals Corp.
- 257 Simarano Drive
- Suite 101
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PHIO||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||May 2012|
|44R2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2012|
|0N34||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 2012|
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer in the United States. The company’s lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone for the clearance of common warts; and RXI-231, an sd-rxRNA compound targeting tyrosinase for use as a cosmetic ingredient that enhances the appearance of uneven skin tone and pigmentation. In addition, it develops RXI-109 that reduces the progression of retinal scarring. The company has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/17 22:09|
|End of Day Share Price||2020/02/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.